Join

Compare · CI vs MDXH

CI vs MDXH

Side-by-side comparison of The Cigna Group (CI) and MDxHealth SA (MDXH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CI and MDXH operate in Medical Specialities (Health Care), so they compete in similar markets.
  • CI is the larger of the two at $76.61B, about 2731.7x MDXH ($28.0M).
  • Over the past year, CI is down 6.3% and MDXH is down 73.6% - CI leads by 67.3 points.
  • MDXH has been more active in the news (10 items in the past 4 weeks vs 4 for CI).
  • CI has more recent analyst coverage (25 ratings vs 5 for MDXH).
PerformanceCI-6.33%MDXH-73.64%
2025-06-09+0.00%2026-06-09
MetricCIMDXH
Company
The Cigna Group
MDxHealth SA
Price
$291.57+0.72%
$0.58+5.32%
Market cap
$76.61B
$28.0M
1M return
+1.20%
-71.14%
1Y return
-6.33%
-73.64%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
4
10
Recent ratings
25
5
CI

The Cigna Group

Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

MDXH

MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.